Northern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Northern Trust Corp raised its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 21.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,523 shares of the company’s stock after acquiring an additional 42,923 shares during the period. Northern Trust Corp owned approximately 0.83% of Dianthus Therapeutics worth $5,352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also modified their holdings of the company. Alliancebernstein L.P. raised its holdings in shares of Dianthus Therapeutics by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock worth $25,283,000 after acquiring an additional 136,633 shares in the last quarter. FMR LLC raised its holdings in Dianthus Therapeutics by 0.8% during the 4th quarter. FMR LLC now owns 4,439,281 shares of the company’s stock valued at $96,776,000 after buying an additional 36,133 shares during the period. Walleye Capital LLC raised its holdings in Dianthus Therapeutics by 176.3% during the 4th quarter. Walleye Capital LLC now owns 82,890 shares of the company’s stock valued at $1,807,000 after buying an additional 52,890 shares during the period. Barclays PLC raised its holdings in Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company’s stock valued at $933,000 after buying an additional 1,082 shares during the period. Finally, SG Americas Securities LLC raised its holdings in Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after buying an additional 814 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have commented on DNTH. Guggenheim reaffirmed a “buy” rating and issued a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Wedbush reissued an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Finally, Robert W. Baird reduced their price target on Dianthus Therapeutics from $58.00 to $50.00 and set an “outperform” rating for the company in a research report on Tuesday, May 13th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and a consensus price target of $53.00.

Dianthus Therapeutics Trading Down 0.8%

Shares of DNTH stock opened at $19.11 on Wednesday. The company has a market cap of $614.58 million, a price-to-earnings ratio of -7.64 and a beta of 1.48. The stock has a 50 day simple moving average of $19.30 and a 200-day simple moving average of $21.99. Dianthus Therapeutics, Inc. has a 12-month low of $13.37 and a 12-month high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The firm had revenue of $1.16 million during the quarter, compared to the consensus estimate of $0.81 million. On average, equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.